Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with prostate cancer (specifically a type called adenocarcinoma, confirmed by a tissue test).
• People who have at least one sign of cancer that has spread, visible on a CT scan or bone scan.
• People whose prostate cancer is getting worse, shown by PSA levels rising at least twice in a row above their lowest recorded level, with a PSA of at least 2 ng/ml — this applies only to the "Intrinsic Resistance" group taking a certain class of hormone-blocking drugs.
• People who a doctor considers suitable for a second-generation hormone-blocking drug (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or a type of radiation treatment called Lu177-PSMA therapy — this applies to the "Intrinsic Resistance" group only.
• Men aged 18 or older.
• People who are able to follow all study procedures, including lying flat and still for at least 30 minutes during imaging scans.
• People who have been fully informed about the research nature of the study and its risks, and who have signed an ethics-approved consent form.
• People with a life expectancy of at least 12 months.
• People who are currently taking a second-generation hormone-blocking drug, whose PSA levels first went down on that treatment but have since risen above their lowest recorded level — and who are enrolled within 12 weeks of that first recorded PSA rise. This applies to the "Acquired Resistance" group only.

Who may not be able to join:

• People with poorly controlled diabetes (fasting blood sugar above 200 mg/dL, or who cannot safely stop diabetes medication or fast for 6 hours before a specific type of scan called an FDG PET scan).
• People who have previously been treated with a second-generation hormone-blocking drug for prostate cancer that had already spread — this applies to the "Intrinsic Resistance" AR-inhibitor group only. Prior use of these drugs before or after surgery (in a non-metastatic setting) may be acceptable, unless the cancer progressed while on that treatment (confirm with trial site).
• People experiencing pain or other symptoms from cancer that has spread, which require opioid-based pain relief.
• People with a specific aggressive subtype of prostate cancer called neuro-endocrine prostate cancer.
• People who have previously received radioactive isotope treatment for castration-resistant prostate cancer.
• People who are incarcerated, people who are unable to give their own informed consent, and people who do not speak English will not be considered for this trial, in order to protect against unintended pressure to participate.

Important: Always verify eligibility with the trial site directly before applying.